ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity.